Browse NCR2

Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF07686 Immunoglobulin V-set domain
Function

Cytotoxicity-activating receptor that may contribute to the increased efficiency of activated natural killer (NK) cells to mediate tumor cell lysis.

> Gene Ontology
 
Biological Process GO:0006968 cellular defense response
Molecular Function -
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04650 Natural killer cell mediated cytotoxicity
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-2172127: DAP12 interactions
R-HSA-168256: Immune System
R-HSA-198933: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
R-HSA-168249: Innate Immune System
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NCR2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NCR2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23580577LymphomaPromote immunityMarked elevations in expression of activation receptors, natural cytotoxicity receptors (NKp30, NKp44), and adhesion molecules (CD11a, ICAM-1) were associated with high tumor-lytic capacity, in both in vitro and in vivo models.
22258454MelanomaPromote immunity (NK cell function)We found that melanoma cells inhibited the expression of major NK receptors that trigger their immune function, including NKp30, NKp44, and NKG2D, with consequent impairment of NK cell-mediated cytolytic activity against various melanoma cell lines. This inhibitory effect was primarily mediated by indoleamine 2,3-dioxygenase (IDO) and prostaglandin E2 (PGE2).
19934056MelanomaPromote immunity (NK cell function)Thus, both the IL-2-induced up-regulation of the surface expression of NKp44, NKp30, and DNAM-1 triggering receptors and the acquisition of cytolytic granules were inhibited in NK cells. This resulted in an impairment of the NK cell-mediated killing of melanoma target cells.
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NCR2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NCR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5550.605
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6050.701
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-2.0170.255
729033130MelanomaallAnti-PD-1 (nivolumab) 262301
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 151101
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 111201
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 4801
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 2801
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0730.609
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NCR2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211714.3014.30.238
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86250250.473
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NCR2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NCR2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NCR2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NCR2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NCR2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NCR2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNCR2
Namenatural cytotoxicity triggering receptor 2
Aliases NK-p44; CD336; LY95; lymphocyte antigen 95 (activating NK-receptor; NK-p44); NKP44; dJ149M18.1; NK cell acti ......
Chromosomal Location6p21.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NCR2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.